Jason R Stubbs
Overview
Explore the profile of Jason R Stubbs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jansson K, Kuluva J, Zhang S, Swanson T, Zhang Y, Zimmerman K, et al.
Physiol Rep
. 2024 Sep;
12(17):e70038.
PMID: 39238069
Osteopontin (OPN) is a multi-functional glycoprotein that coordinates the innate immune response, prevents nanocrystal formation in renal tubule fluid, and is a biomarker for kidney injury. OPN expression is markedly...
2.
Swenson-Fields K, Ward C, Lopez M, Fross S, Heimes Dillon A, Meisenheimer J, et al.
Front Mol Biosci
. 2022 Dec;
9:971219.
PMID: 36523654
We and others have previously shown that the presence of renal innate immune cells can promote polycystic kidney disease (PKD) progression. In this study, we examined the influence of the...
3.
Rowe P, McCarthy E, Yu A, Stubbs J
Kidney360
. 2022 Dec;
3(10):1683-1698.
PMID: 36514737
Background: Abnormalities in calcium, phosphorus, PTH, vitamin D metabolism, bone, and vascular calcification occur in chronic kidney disease mineral bone disorder (CKD-MBD). Calciphylaxis, involving painful, ulcerative skin lesions, is also...
4.
Stubbs J, Zhang S, Jansson K, Fields T, Boulanger J, Liu S, et al.
Kidney360
. 2022 Oct;
3(9):1578-1589.
PMID: 36245654
Background: Nephron loss dramatically increases tubular phosphate to concentrations that exceed supersaturation. Osteopontin (OPN) is a matricellular protein that enhances mineral solubility in solution; however, the role of OPN in...
5.
Riddle H, Zhang S, Qian F, Williams Jr J, Stubbs J, Rowe P, et al.
Am J Physiol Renal Physiol
. 2022 Mar;
323(1):F59-F68.
PMID: 35343849
Individuals with autosomal dominant polycystic kidney disease have a higher incidence of stone formation than the general population. However, there are no cystic animal models known to develop stones. Cystic...
6.
Jansson K, Yu A, Stubbs J
Curr Opin Nephrol Hypertens
. 2022 Mar;
31(4):306-311.
PMID: 35283435
Purpose Of Review: Progressive forms of chronic kidney disease (CKD) exhibit kidney inflammation and fibrosis that drive continued nephron loss; however, factors responsible for the development of these common pathologic...
7.
Kimber C, Zhang S, Johnson C, West 3rd R, Prokopienko A, Mahnken J, et al.
Kidney360
. 2021 Jul;
1(11):1206-1216.
PMID: 34322673
Background: Recent evidence suggests the systemic accumulation of by-products of gut microbes contributes to cardiovascular morbidity in patients with CKD. Limiting the generation of toxic bacterial by-products by manipulating the...
8.
Yu A, El Ters M, Stubbs J
Kidney Int Rep
. 2021 May;
6(5):1482-1483.
PMID: 34013132
No abstract available.
9.
El Ters M, Lu P, Mahnken J, Stubbs J, Zhang S, Wallace D, et al.
Kidney Int Rep
. 2021 Apr;
6(4):953-961.
PMID: 33912745
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and a loss of functioning renal mass, but a decline in glomerular filtration rate (GFR) and onset...
10.
Oakley C, Vallejo J, Wang D, Gray M, Tiede-Lewis L, Shawgo T, et al.
Am J Physiol Heart Circ Physiol
. 2020 Apr;
318(5):H1272-H1282.
PMID: 32243768
Cardiovascular disease is a major cause of morbidity and mortality among patients with chronic kidney disease (CKD). Trimethylamine--oxide (TMAO), a uremic metabolite that is elevated in the setting of CKD,...